Lee's Pharmaceutical Holdings Ltd

00950

Company Profile

  • Business description

    Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People’s Republic of China.

  • Contact

    Hong Kong Science Park
    1st Floor, Building 20E, Phase 3
    Shatin
    Hong Kong
    HKG

    T: +852 23141282

    https://www.leespharm.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    1,036

Stocks News & Analysis

stocks

Is this ASX share a value trap or bargain?

Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks

Goldman Sachs Earnings: Valuations remain stretched

We raise our fair value estimate for Goldman Sachs stock.
stocks

Major ASX listed miners overvalued

We’ve adjusted our fair values after updating our commodity price assumptions.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,194.9012.40-0.13%
CAC 408,112.02146.92-1.78%
DAX 4024,959.06338.07-1.34%
Dow JONES (US)49,359.3383.11-0.17%
FTSE 10010,195.3539.94-0.39%
HKSE26,563.90281.06-1.05%
NASDAQ23,515.3914.63-0.06%
Nikkei 22553,583.57352.60-0.65%
NZX 50 Index13,580.770.480.00%
S&P 5006,940.014.46-0.06%
S&P/ASX 2008,874.509.20-0.10%
SSE Composite Index4,114.0012.090.29%

Market Movers